Illinois, USA-based Winston Laboratories, a wholly-owned subsidiary of Getting Ready Corp, has entered into a licensing agreement with French-owned Sanofi-Aventis Canada for the Canadian rights to its proprietary transient receptor potential vanilloid (TRPV-1) modulator in formulations for topical application.
On October 29, Winston filed a new drug submission in Canada for the first product it has developed under its technology, Civanex Cream (civamide 0.075%) for the treatment of signs and symptoms of osteoarthritis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze